Ascentage Pharma Group International Unsponsored ADR (AAPG)
NASDAQ:AAPG
Want to see AAPG full AI Analyst Report?
Top Page
Ascentage Pharma Group International Unsponsored ADR
(NASDAQ:AAPG)
Select Model
Select Model
Rating:42Neutral
Price Target:
$22.50
▼(-17.88% Downside)
Action:UpgradedDate:01/08/26
The score is primarily held back by weak financial quality (ongoing losses, negative cash flow, and high leverage risk) and bearish technical conditions (negative MACD and price below key moving averages). Rapid revenue growth provides some offset, but valuation signals are limited due to negative earnings and no dividend data.
Positive Factors
FDA IND clearance for APG-3288
FDA IND clearance for APG-3288 validates Ascentage's PROTAC-based BTK degrader approach and allows a global Phase I program. This regulatory milestone expands the company’s innovative hematology pipeline and creates durable R&D optionality to address BTK inhibitor resistance.
Negative Factors
Persistent unprofitability and negative margins
Ongoing negative net income and negative EBIT/EBITDA margins indicate the business has not reached operational profitability. Sustained losses constrain reinvestment, increase financing reliance, and raise execution risk for costly late‑stage trials and global commercialization over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
FDA IND clearance for APG-3288
FDA IND clearance for APG-3288 validates Ascentage's PROTAC-based BTK degrader approach and allows a global Phase I program. This regulatory milestone expands the company’s innovative hematology pipeline and creates durable R&D optionality to address BTK inhibitor resistance.
Read all positive factors
Ascentage Pharma Group International Unsponsored ADR (AAPG) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.18B
Dividend YieldN/A
Average Volume (3M)8.43K
Price to Earnings (P/E)―
Beta (1Y)0.72
Revenue Growth-41.19%
EPS Growth-159.09%
CountryUS
Employees567
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.04
Shares Outstanding93,330,550
10 Day Avg. Volume7,086
30 Day Avg. Volume8,425
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)36.26
Price to Sales (P/S)9.77
P/FCF Ratio-70.62
Enterprise Value/Market Cap6.33
Enterprise Value/Revenue35.32
Enterprise Value/Gross Profit38.87
Enterprise Value/Ebitda-13.24
Forecast
1Y Price Target
$41.56Price Target Upside51.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.1
Revenue Forecast (FY)$134.34M
Ascentage Pharma Group International Unsponsored ADR Business Overview & Revenue Model
Company Description
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-AB...
How the Company Makes Money
Ascentage Pharma generates revenue primarily through the development and commercialization of its pharmaceutical products. The company focuses on advancing its drug candidates through clinical trials and regulatory approval processes, with the pot...
Ascentage Pharma Group International Unsponsored ADR Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
30
Negative
Cash Flow
40
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 390.60M | 980.65M | 221.98M | 209.71M | 27.91M | 12.45M |
| Gross Profit | 354.93M | 951.57M | 191.44M | 187.71M | 24.58M | 10.48M |
| EBITDA | -1.04B | -237.63M | -743.61M | -786.97M | -798.34M | -652.23M |
| Net Income | -1.16B | -405.43M | -925.64M | -882.92M | -782.42M | -677.61M |
Balance Sheet | ||||||
| Total Assets | 3.05B | 2.62B | 2.50B | 2.83B | 2.94B | 1.73B |
| Cash, Cash Equivalents and Short-Term Investments | 1.66B | 1.24B | 1.07B | 1.48B | 1.71B | 1.02B |
| Total Debt | 1.72B | 1.67B | 1.80B | 1.79B | 1.08B | 529.70M |
| Total Liabilities | 2.37B | 2.34B | 2.43B | 2.42B | 1.71B | 884.42M |
| Stockholders Equity | 666.00M | 264.19M | 60.42M | 408.66M | 1.23B | 846.62M |
Cash Flow | ||||||
| Free Cash Flow | 235.27M | -135.65M | -782.92M | -890.88M | -1.04B | -861.43M |
| Operating Cash Flow | 243.03M | -111.36M | -726.08M | -653.91M | -604.68M | -609.96M |
| Investing Cash Flow | -230.76M | -362.04M | 21.92M | -384.61M | -466.52M | -107.37M |
| Financing Cash Flow | -82.14M | 314.77M | 368.75M | 619.27M | 1.78B | 1.04B |
Ascentage Pharma Group International Unsponsored ADR Technical Analysis
Negative
27.40
Price Trends
37.24
Negative
38.97
Negative
Market Momentum
-1.44
Positive
34.89
Neutral
11.49
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AAPG, the sentiment is Negative. The current price of 27.4 is below the 20-day moving average (MA) of 34.27, below the 50-day MA of 37.24, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of -1.44 indicates Positive momentum. The RSI at 34.89 is Neutral, neither overbought nor oversold. The STOCH value of 11.49 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AAPG.
Ascentage Pharma Group International Unsponsored ADR Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $6.29B | -31.28 | -19.89% | ― | -89.41% | -145.57% | |
62 Neutral | $5.83B | -10.43 | -65.80% | ― | ― | -2.53% | |
59 Neutral | $7.08B | -21.09 | -29.08% | ― | -16.70% | -24.00% | |
55 Neutral | $4.04B | -8.91 | -41.46% | ― | ― | -33.52% | |
54 Neutral | $1.21B | -3.74 | -67.12% | ― | ― | -86.55% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
42 Neutral | $2.18B | -13.51 | -123.61% | ― | -41.19% | -159.09% |
* Healthcare Sector Average
AAPG
Ascentage Pharma Group International Unsponsored ADR
23.00
-1.43
-5.85%
PTGX
Protagonist Therapeutics
101.21
55.39
120.89%
CRNX
Crinetics Pharmaceuticals
38.15
4.76
14.26%
IMVT
Immunovant
26.99
10.84
67.12%
KYMR
Kymera Therapeutics
83.85
49.58
144.67%
MLTX
MoonLake Immunotherapeutics
16.66
-25.42
-60.41%
Ascentage Pharma Group International Unsponsored ADR Corporate Events
Ascentage Pharma Details 2026 Global Innovation Strategy at J.P. Morgan Healthcare Conference
Jan 15, 2026
At the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, Ascentage Pharma’s chairman and CEO Dajun Yang reviewed the company’s 2025 milestones and laid out a global innovation strategy for 2026 centered on its growing ...
Ascentage Pharma Wins FDA IND Clearance for BTK Degrader APG-3288 to Enter Global Phase I Trial
Jan 7, 2026
On January 6, 2026, Ascentage Pharma Group International announced that the U.S. Food and Drug Administration had granted investigational new drug clearance for APG-3288, a novel next-generation Bruton tyrosine kinase (BTK)-targeted protein degrad...
Ascentage Pharma to Present at J.P. Morgan Healthcare Conference
Dec 17, 2025
On December 17, 2025, Ascentage Pharma announced its participation in the 44th Annual J.P. Morgan Healthcare Conference scheduled for January 14, 2026, in San Francisco, CA. The company’s management plans to present their advancements in bio...
Ascentage Pharma Showcases Promising Data for Olverembatinib at ASH 2025
Dec 9, 2025
On December 8, 2025, Ascentage Pharma presented updated data on Olverembatinib at the ASH Annual Meeting, showcasing its potential as a second-line treatment for chronic myeloid leukemia in chronic-phase (CML-CP). The data revealed a 76.7% complet...
Ascentage Pharma Unveils Promising Lisaftoclax Data at ASH 2025
Dec 8, 2025
On December 6 and December 8, 2025, Ascentage Pharma presented significant data at the American Society of Hematology Annual Meeting regarding Lisaftoclax, a Bcl-2 inhibitor. The data from the Phase II study demonstrated Lisaftoclax’s effica...
Ascentage Pharma to Highlight Key Data from ASH 2025 in Upcoming Webcast
Dec 1, 2025
On December 1, 2025, Ascentage Pharma announced it will host an investor webcast on December 11, 2025, to highlight key data from the 67th American Society of Hematology Annual Meeting. This event will provide updates on the company’s innova...
Ascentage Pharma Announces New RSU and Share Option Grants
Nov 28, 2025
On November 27, 2025, Ascentage Pharma Group International announced the further grant of awards under its 2022 RSU Scheme and the grant of options under the Post IPO Share Option Scheme. This initiative involves the allocation of 1,304,457 RSUs t...
Ascentage Pharma’s Olverembatinib Shows Promise in Rare GIST Treatment
Nov 25, 2025
On November 24, 2025, Ascentage Pharma announced the publication of promising Phase Ib clinical trial results for olverembatinib in treating succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GIST), a rare and challenging can...
Ascentage Pharma to Engage Investors at December 2025 Conferences
Nov 19, 2025
On November 19, 2025, Ascentage Pharma announced its participation in three investor conferences in December 2025, signaling its active engagement with the investment community. This participation could enhance the company’s visibility and i...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.